US Pat. No. 10,711,315

METHOD FOR PRODUCING RNA

1. A method for producing purified mRNA on a preparative scale comprising the following steps:a) providing a template DNA comprising a nucleic acid sequence encoding a mRNA sequence;
b) in vitro transcription of the template DNA in order to obtain a composition comprising the mRNA;
c) purification of a preparative quantity of the mRNA obtained in step b) by purification steps comprising, at least:
i) oligo dT-based affinity purification; and
ii) RP-HPLC,
thereby producing a preparative quantity of purified mRNA.
US Pat. No. 10,709,779

NUCLEIC ACID VACCINES

ModernaTX, Inc., Cambrid...

1. A method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more messenger ribonucleic acid (mRNA) polynucleotides comprising an open reading frame encoding an antigenic polypeptide that is derived from an infectious agent, wherein the mRNA polynucleotide is not self-replicating RNA, wherein the mRNA polynucleotides are formulated within a cationic lipid nanoparticle having a molar ratio of about 20-60% ionizable cationic lipid: about 5-25% non-cationic lipid: about 25-55% sterol; and about 0.5-15% PEG-modified lipid, wherein the nucleic acid vaccine elicits an immune response having a longer lasting antibody titer than an antibody titer elicited by a reference nucleic acid vaccine comprising the one or more mRNA polynucleotides not formulated within a cationic lipid nanoparticle having a molar ratio of about 20-60% ionizable cationic lipid: about 5-25% non-cationic lipid: about 25-55% sterol; and about 0.5-15% PEG-modified lipid.
US Pat. No. 10,711,060

ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF

NOVARTIS AG, (CH) Immute...

1. An isolated nucleic acid molecule comprising a first nucleotide sequence that encodes a VH and a second nucleotide sequence that encodes a VL of an antibody molecule that binds to human LAG-3, wherein the antibody molecule comprises:(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 4, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15;
(b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12;
(c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15; or
(d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12.
US Pat. No. 10,711,316

PRIMERS AND KITS FOR COLONY MULTIPLEX PCR FOR THE DETECTION OF CLASS A, B, C, AND D BETA-LACTAMASE GENES AND METHODS OF USING THEREOF

MYONGJI UNIVERSITY INDUST...

1. A method for treating a patient with bacterial infection, the method comprising:determining a ?-lactamase (bla) gene of a bacterial pathogen in the patient by performing a multiplex polymerase chain reaction (PCR) with primer pairs;
determining a ?-Lactam antibiotics to which the bacterial pathogen is not resistant, in accordance with the determination of the ?-lactamase (bla) gene; and
administering the ?-Lactam antibiotics to the patient,
wherein the primer pairs comprise:
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 1 and 2, a pair of Seq. 3 and 4, a pair of Seq. No. 5 and 6, a pair of Seq. No. 7 and 8, a pair of Seq. No. 9 and 10, a pair of Seq. No. 11 and 12, a pair of Seq. No. 13 and 14, and a pair of Seq. No. 15 and 16;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 17 and 18, a pair of Seq. No. 19 and 20, a pair of Seq. No. 21 and 22, a pair of Seq. No. 23 and 24, and a pair of Seq. No. 25 and 26;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 27 and 28, a pair of Seq. No. 29 and 30, a pair of Seq. No. 31 and 32, a pair of Seq. No. 33 and 34, a pair of Seq. No. 35 and 36, a pair of Seq. No. 37 and 38, a pair of Seq. No. 39 and 40, and a pair of Seq. No. 41 and 42;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 43 and 44, a pair of Seq. No. 45 and 46, a pair of Seq. No. 47 and 48, a pair of Seq. No. 49 and 50, a pair of Seq. No. 51 and 52, a pair of Seq. No. 53 and 54, No. 55 and 56, and a pair of Seq. 57 and 58;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 59 and 60, a pair of Seq. No. 61 and 62, a pair of Seq. No. 63 and 64, a pair of Seq. No. 65 and 66, and a pair of Seq. No. 67 and 68;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 69 and 70, a pair of Seq. No. 71 and 72, a pair of Seq. No. 73 and 74, a pair of Seq. No. 75 and 76, a pair of Seq. No. 77 and 78;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 79 and 80, a pair of Seq. No. 81 and 82, a pair of Seq. No. 83 and 84, a pair of Seq. No. 85 and 86, a pair of Seq. No. 87 and 88, a pair of Seq. No. 89 and 90, a pair of Seq. No. 91 and 92, and a pair of Seq. No. 93 and 94; and
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 95 and 96, a pair of Seq. No. 97 and 98, a pair of Seq. No. 99 and 100, a pair of Seq. No. 101 and 102, a pair of Seq. No. 103 and 104, a pair of Seq. No. 105 and 106, and a pair of Seq. No. 107 and 108.
US Pat. No. 10,709,780

INTEGRIN ACTIVATOR VACCINE COMPOSITIONS

7 Hills Pharma LLC, Hous...

1. A composition comprising:(A) an antigen, and
(B) an adjuvanting amount of at least one integrin activating compound that increases an immune response to the antigen,
wherein the at least one integrin activating compound comprises one or more compounds of the general Formula (I):
R1-M1-N(R2)-M2-M3-M4-M5-M6-R3  (I)
wherein a first class of the compounds of Formula (I) is defined by:
R1 is selected from the group consisting of aryl and aralkyl,
R2 is alkyl, aryl, or aralkyl,
M1 is CH2,
M2 is CO,
M3 is O, S, or NR6,
R6 when present is hydrogen or lower alkyl,
M4 is absent or CH2,
M5 is (CR11R12),
R11 is hydrogen,
R12 is selected from the group consisting of hydrogen, NR21CONR22R23, NR21COR24, NR21SO2R24, NR21COOR24, OCOR24, OR24, O(CH2CH2O)sR24, COOR24, alkyl, and hydroxyalkyl,
s is an integer of 1 to 6,
R21 and R22 when present are independently selected from the group consisting of hydrogen or lower alkyl,
R23 when present is selected from the group consisting of hydroxyalkyl, alkoxyalkyl, alkyl, aryl, aralkyl and alkoxycarbonylalkyl,
 provided that when M3 is NR6 and M4 is absent, then R23 is not 1-(1,3-benzodioxol-5-yl)-3-ethoxy-3-oxopropyl,
R24 when present is selected from the group consisting of alkyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkylalkyl, and heterocyclylalkyl, and mixtures thereof,
M6 is (CH2)q, where
q is an integer from 0 to 6,
R3 is selected from the group consisting of hydrogen, CONR13R14, NR15COOR16, NR15COR16, NR15CONR13R14, NR15SO2R16, OCOR16, COOR16, OR16, SR16, heterocyclyl, hydroxyl, hydroxyalkyl, guanadino, alkyl and aryl,
R13 and R15 when present are independently hydrogen or lower alkyl,
R14 and R16 when present are independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, and heterocyclylalkyl,
R1, R2, R3, R12, R14, R16, R23 and R24 when present may independently be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino), —OCO(dialkylamino), and mixtures thereof;orwherein a second class of the compounds of Formula (I) is defined by:
R1 is aryl or aralkyl,
R2 is alkyl or aralkyl,
M1 is CH2,
M2 is CO,
M3 is absent or is O or CH2,
M4 is absent or is CH2,
M5 is absent or is O or (CR11R12),
R11 is hydrogen,
R12 is selected from the group consisting of hydrogen, NR21CONR22R23,
NR21COR24, NR21SO2R24 and NR21COOR24,
R21 and R22 each of which, when present is independently selected from the group of hydrogen and lower alkyl,
R23 and R24, each of which, when present is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl,
M6 is selected from the group consisting of (CH2)q, (CH2)q—CH?CH—(CH2)r, (CH2)q-arylene-(CH2)r and (CH2CH2O)q, where
q and r are independently integers from 0 to 6,
R3 is CONR13R14,
R13 and R14, each of which, when present is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl, and
R1, R2, R13, R14, R23 and R24, when present, independently either are unsubstituted or are substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino), —OCO(dialkylamino), and mixtures thereof;orwherein a third class of the compounds of Formula (I) is defined by:
R1 is aryl or aralkyl,
R2 is alkyl or aralkyl,
M1 is CH2,
M2 is SO2, or CO,
M3 is absent or is CH2,
M4 is absent or is CH2,
M5 is absent or is (CR11R12),
R11, when present, is hydrogen,
R12, when present, is selected from the group consisting of hydrogen, alkyl,
NR21CONR22R23, NR21COR24, NR21SO2R24 and NR21COOR24,
R21 and R22, each of which when present, is independently selected from the group of hydrogen, lower alkyl, and aralkyl,
R23 and R24, each of which, when present is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl,
M6 is (CH2)q, or NR34(CH2)q,
q is an integer from 0 to 6,
R34, when present, is selected form the group consisting of alkyl, aralkyl, COR35, and SO2R35,
R35 when present, is selected form the group consisting of alkyl, aryl, and aralkyl, and
R3 is selected from the group consisting of CONR13R14, SO2NR13R14, NR15COOR16, NR15COR16, NR15CONR13R14, and NR15SO2R16,
R13 and R14, each of which, when present, is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl,
R15 and R16, each of which when present, is independently selected from the group of hydrogen, lower alkyl, and aralkyl,
R1, R2, R13, R14, R15, R16, R23, R24, R34 and R35, when present, either are unsubstituted or are substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino), and —OCO(dialkylamino), with the proviso that when M2 is CO, then M6 is NR34(CH2)q,
wherein q is not 0;orwherein a four class of the compounds of Formula (I) is defined by:
R1 is alkyl, aryl or aralkyl,
R2 is selected from the group consisting of aralkyl and alkyl,
provided that when R1 is alkyl, R2 is aralkyl,
M1 is CO or SO2,
provided that when M1 is SO2 and R1 is phenyl, 4-methylphenyl or 2,4,6-trimethylphenyl, R2 is not alkyl, 2-phenethyl, benzyl, or 2-methoxy-2-oxoethyl, and when M1 is CO and R1 is 2-furyl, 4-pyridyl, or 3,5-dinitrophenyl, R2 is not alkyl, benzyl or 2-(1H-indol-2-yl)ethyl,
M2 is absent or CH2,
M3 and M4 are absent,
M5 is (CR11R12),
R11 is hydrogen,
R12 is selected from the group consisting of hydrogen, NR21CONR22R23, NR21COR24, NR21SO2R24, NR21COOR24, CONR22R23, COOR24, O(CH2CH2O)sR24, hydroxyalkyl, and alkoxyalkyl,
R21, and R22, when present, are independently selected from the group consisting of hydrogen and C1-C6 alkyl, and
R23 and R24, each of which, when present, is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl, and
s is an integer of 1 to 6,
M6 is (CH2)q,
q is an integer of 0 to 6,
R3 is selected from the group consisting of NR15COOR16, NR15COR16, NR15CONR13R14, and NR15SO2R16, and
R13 when present, is independently selected from the group consisting of hydrogen and C1-C6 alkyl, and
R14, R15, and R16 each of which, when present, are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl, and
R1, R2, R3, R12, R14, R15, R16, R23, and R24, when present, independently either are unsubstituted or are substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino) and —OCO(dialkylamino),orpharmaceutically acceptable salts thereof.
US Pat. No. 10,711,061

ANTIBODIES AGAINST CANINE PD-1

Intervet Inc., Madison, ...

1. An isolated mammalian antibody or an antigen binding fragment thereof, that binds canine Programmed Death Receptor 1 (canine PD-1) with specificity, said antibody comprising a set of six complementary determining regions (CDRs) that comprises three light chain CDRs: CDR light 1 (CDRL1), CDR light 2 (CDRL2), and CDR light 3 (CDRL3); and three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2) and CDR heavy 3 (CDRH3);(a) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 13;
(b) wherein CDRL2 comprises the amino acid sequence of SEQ ID NO: 19;
(c) wherein CDRL3 comprises the amino acid sequence of SEQ ID NO: 25;
(d) wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 27;
(e) wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 31; and
(f) wherein CDRH3 comprises the amino acid sequence of SEQ ID NO: 36.
US Pat. No. 10,712,341

BIOSENSOR

Duke University, Durham,...

1. A method of assaying for glutamate in a sample, comprising contacting a biosensor with said sample under conditions such that said biosensor is able to bind to glutamate present in said sample, wherein said biosensor comprises Escherichia coil E. coli) glutamate/aspartate binding protein (EBP) comprising a reporter group attached at amino acid position 126 of said E. coil EBP, wherein said E. coli EBP comprises the amino acid sequence set forth in SEQ ID NO: 3, and wherein binding of glutamate in a glutamate-binding pocket of said biosensor causes a change in signaling by said reporter group.
US Pat. No. 10,711,062

ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF

ALECTOR LLC, South San F...

1. An antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region comprising an HVR-H1, HVR-H2, and HVR-H3 and a light chain variable region comprising an HVR-L1, HVR-L2, and HVR-L3, whereinthe HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 115, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146;
the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 118, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146;
the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 119, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146; or
the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 120, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146.
US Pat. No. 10,711,318

MICROBIAL STRAIN FOR ELECTROSYNTHESIS AND ELECTROFERMENTATION

UNIVERSITY OF MASSACHUSET...

1. A genetically engineered Geobacter sulfurreducens strain, wherein the strain comprises a genetically engineered modification resulting from the insertion of a genetic element encoding ATP-citrate lyase (EC 2.3.3.8), wherein the strain is capable of effectively growing on a cathode under anaerobic conditions with electrons derived solely from the cathode as electron donor source.
US Pat. No. 10,712,342

DIAGNOSTIC TO DISTINGUISH BACTERIAL INFECTIONS

Arizona Board of Regents ...

1. An array comprising at least two peptides that are capable of differentially binding to one or more antibodies produced in response to a bacterial infection or to one or more antibodies produced in response to a viral infection, wherein said array comprises SEQ ID NO.1 and SEQ ID NO.2.
US Pat. No. 10,709,782

STABLE ANTIBODY CONTAINING COMPOSITIONS

1. A stable, liquid composition comprising an anti-NKG2A monoclonal antibody, arginine, a salt and a buffer, wherein the total concentration of said salt and buffer is lower than 100 mM, wherein the composition comprises:(a) 100 mg/ml of the anti-NKG2A antibody;
(b) 25 mM sodium chloride;
(c) 33 mM histidine buffer;
(d) 25 mM arginine; and
(e) 150 mM sucrose;
buffered to a pH between 5 and 7.
US Pat. No. 10,711,063

NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES

INNATE PHARMA, Marseille...

1. A method of treating a cancer in a human patient, the method comprising administering to the patient an effective amount of each of: (a) an antibody that neutralizes human NKG2A, and (b) an antibody that neutralizes human PD-L1, wherein the antibody that neutralizes human NKG2A comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in any one of SEQ ID NOS: 4-8, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 9 and the antibody that neutralizes human PD-L1 is selected from nivolumab, lambrolizumab, pembrolizumab, atezolizumab, or pidlizumab.
US Pat. No. 10,711,319

METHOD FOR TREATING CELLULOSIC MATERIAL

SilvaNova, LLC, Plymouth...

1. A method comprising(i) contacting a cellulose-comprising input material with an aqueous hydrolyzing solution comprising at least 35% wt. of at least one mineral acid to form a hydrolyzate comprising a mixture of water-soluble carbohydrates and optionally a solid fraction;
(ii) contacting said hydrolyzate with an extractant comprising a first solvent S1, to form (a) a solid first residue comprising precipitated carbohydrates and (b) an acid-comprising extract;
(iii) separating said acid-comprising extract from said solid first residue;
(iv) modifying said acid-comprising extract to form (a) a liquid second residue comprising dissolved carbohydrates and (b) an acid-comprising modified extract, wherein said modifying said acid-comprising extract comprises combining said extract with a second solvent S2;
(v) fractionating said modified extract into an S1-enriched fraction and an acid-enriched fraction;
(vi) reusing said S1-enriched fraction to form said extractant; and
(vii) reusing said acid-enriched fraction to form said aqueous hydrolyzing solution; wherein
(a) at least 10% wt. of the cellulose is hydrolyzed and said mixture of water-soluble carbohydrates comprises monosaccharides, disaccharides and/or oligosaccharides;
(b) S1 forms a single phase when mixed with an identical weight of 70% sulfuric acid aqueous solution at 25° C.;
(c) S1 is at least 65% wt. of said extractant; and
(d) said acid-comprising extract comprises at least 60% wt. of the acid and at least 5% wt. of the carbohydrates in said hydrolyzate.
US Pat. No. 10,712,343

MOLECULAR ANALYSIS OF TUMOR SAMPLES

The General Hospital Corp...

1. A method for treating an intra-abdominal tumor in a subject, the method comprising:obtaining a sample from the subject, wherein the sample is not from breast or lung tissue;
detecting levels of biomarkers consisting of MUC-1, HER2, EGFR, and EpCAM in the sample by contacting the sample with antibodies or antigen-binding fragments thereof that bind to MUC-1, HER2, EGFR, and EpCAM and are labeled with superparamagnetic cross-linked iron oxide (CLIO) nanoparticles having a hydrodynamic diameter of 28.8 nm;
comparing the levels of MUC-1, HER2, EGFR, and EpCAM in the sample to reference levels; and
administering a treatment for cancer to a subject who has levels of MUC-1, HER2, EGFR, and EpCAM above the reference levels.
US Pat. No. 10,711,064

LYM-1 AND LYM-2 TARGETED CAR CELL IMMUNOTHERAPY

University of Southern Ca...

1. A chimeric antigen receptor (CAR) comprising: (a) an antigen binding domain of an anti-HLA-DR antibody; (b) a CD8 ? hinge domain; (c) a CD8 ? transmembrane domain; (d) a CD28 costimulatory signaling region and/or a 4-1BB costimulatory signaling region; and (e) a CD3 zeta signaling domain, wherein the antigen binding domain of an anti-HLA-DR antibody comprises:(i) a heavy chain variable region comprising SEQ ID NO: 8 and a light chain variable region comprising SEQ ID NO: 18; or
(ii) a heavy chain variable region comprising SEQ ID NO: 10 and a light chain variable region comprising SEQ ID NO: 20.
US Pat. No. 10,711,320

REDUCTION AT ELEVATED TEMPERATURE OF COATED STEELS CONTAINING METASTABLE AUSTENITE

AK Steel Properties, Inc....

1. A method of coating a metastable steel comprising the steps of:a. Selecting a metastable steel having an instability factor (IF) greater than or equal to 2.9, wherein IF is calculated by the following equation:
IF=37.193?51.248(% C)?0.4677(% Cr)?1.0174(% Mn)?34.396(% N)?2.5884(% Ni)
b. Prior to coating said metastable steel, annealing said metastable steel;
c. Coating said metastable steel with a metallic coating;
d. After coating said metastable steel, warming said metastable steel to a warming temperature greater than 70° F.; and
e. Rolling said coated and warmed metastable steel.
US Pat. No. 10,714,139

MAGNETIC RECORDING MEDIUM HAVING CHARACTERIZED MAGNETIC LAYER

FUJIFILM Corporation, To...

1. A magnetic recording medium comprising:a non-magnetic support; and
a magnetic layer which is provided on the support and contains ferromagnetic powder and a binder,
wherein the ferromagnetic powder is ferromagnetic hexagonal ferrite powder,
the magnetic layer contains an abrasive,
an intensity ratio (Int (110)/Int (114)) of a peak intensity Int (110) of a diffraction peak of (110) plane of a crystal structure of the hexagonal ferrite, determined by performing X-ray diffraction analysis on the magnetic layer by using an In-Plane method, to a peak intensity Int (114) of a diffraction peak of (114) plane of the crystal structure is equal to or higher than 0.5 and equal to or lower than 4.0,
a squareness ratio of the magnetic recording medium in a vertical direction is equal to or higher than 0.65 and equal to or lower than 1.00, and
a contact angle with 1-bromonaphthalene measured within a surface of the magnetic layer is in a range of 50.0° to 55.00.